Jean Jacques Bienaime, Director at Keros Therapeutics, bought KROS on Jun 15, 2026
Data as of Oct 16
- Traded
- Jun 15, 2026
- Disclosed
- Jun 17, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
KROS since disclosure
+2.4%
Similar stocks (XLV) since disclosure
+17.3%
XLV — its sector index fund
Change in closing price from Jun 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.